18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer

Akira Toriihara; Heying Duan; Holly M Thompson; Sonya Park; Negin Hatami; Lucia Baratto; Alice C Fan; Andrei Iagaru

doi:10.1007/s00259-019-04295-7

¹⁸F-FPPRGD₂ PET/CT in patients with metastatic renal cell cancer

Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1518-1523. doi: 10.1007/s00259-019-04295-7. Epub 2019 Mar 8.

Authors

Akira Toriihara¹, Heying Duan¹, Holly M Thompson², Sonya Park¹, Negin Hatami¹, Lucia Baratto¹, Alice C Fan³, Andrei Iagaru⁴

Affiliations

¹ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.
² Department of Nuclear Medicine, Kaiser Permanente, Santa Clara, CA, USA.
³ Division of Oncology, Department of Medicine, Stanford University, 269 Campus Drive, Stanford, CA, 94305, USA. afan@stanford.edu.
⁴ Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA. aiagaru@stanford.edu.

PMID: 30850872
DOI: 10.1007/s00259-019-04295-7

Abstract

Purpose: The usefulness of positron emission tomography/computed tomography (PET/CT) using (¹⁸F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide [PEG3-E{c(RGDyk)}2] (¹⁸F-FPPRGD₂) in patients with metastatic renal cell cancer (mRCC) has not been evaluated; therefore, we were prompted to conduct this pilot study.

Methods: Seven patients with mRCC were enrolled in this prospective study. ¹⁸F-FPPRGD₂ and 2-deoxy-2-(¹⁸F)fluoro-D-glucose (¹⁸F-FDG) PET/CT images were evaluated in a per-lesion analysis. Maximum standardized uptake value (SUV_max) and tumor-to-background ratio (T/B) were measured for all detected lesions, both before and after starting antiangiogenic therapy.

Results: Sixty lesions in total were detected in this cohort. SUV_max from ¹⁸F-FPPRGD₂ PET/CT was lower than that from ¹⁸F-FDG PET/CT (4.4 ± 2.9 vs 7.8 ± 5.6, P < 0.001). Both SUV_max and T/B from ¹⁸F-FPPRGD₂ PET/CT decreased after starting antiangiogenic therapy (SUV_max, 4.2 ± 3.2 vs 2.6 ± 1.4, P = 0.003; T/B, 3.7 ± 3.2 vs 1.5 ± 0.8, P < 0.001). Average changes in SUV_max and T/B were - 29.3 ± 23.6% and - 48.1 ± 28.3%, respectively.

Conclusions: ¹⁸F-FPPRGD₂ PET/CT may be an useful tool for monitoring early response to antiangiogenic therapy in patients with mRCC. These preliminary results need to be confirmed in larger cohorts.

Keywords: 18F-FDG; 18F-FPPRGD2; Antiangiogenic therapy; PET/CT; Renal cell cancer.

MeSH terms

Aged
Aged, 80 and over
Angiogenesis Inhibitors / therapeutic use
Carcinoma, Renal Cell / diagnostic imaging*
Female
Humans
Kidney Neoplasms / diagnostic imaging*
Male
Middle Aged
Neoplasm Metastasis
Peptides, Cyclic
Pilot Projects
Positron Emission Tomography Computed Tomography*
Prospective Studies

Substances

Angiogenesis Inhibitors
FPP(RGD)2
Peptides, Cyclic

Abstract

MeSH terms

Substances

Grants and funding